In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Celsion (CLSN – Research Report), with a price target of $16.00. The company’s shares opened today at $2.09.
Bodnar covers the Healthcare sector, focusing on stocks such as Celsion, NovoCure, and Olema Pharmaceuticals. According to TipRanks, Bodnar has an average return of -0.7% and a 38.71% success rate on recommended stocks.
The analyst consensus on Celsion is currently a Moderate Buy rating.
See today’s best-performing stocks on TipRanks >>
CLSN market cap is currently $15.12M and has a P/E ratio of -0.15.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Celsion Corp . engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.
Read More on CLSN:
- Stock Market Today – Thursday, September 1: What You Need to Know
- Easing Regulatory Hurdle Puts Alibaba (NYSE:BABA) Stock in the Limelight
- H.C. Wainwright Keeps Their Buy Rating on Pliant Therapeutics (PLRX)
- Chinese EV Companies Report Delivery Numbers; Results aren’t That Great
- Infinity Exchange Brings More Traditional Fixed-Income Approach to DeFi
